

Abuse Deterrent Formulation Science Meeting List of Speakers (in alphabetical order)

Nacer E. Dean Abrouk, Ph.D.

Vice-President of Biometrics & Data Management
Nektar Therapeutics
turbo993@gmail.com

Nagesh Bandi, Ph.D.

Director, Global CMC (Regulatory) –
New Products
Pfizer Global R&D

Todd Baumgartner, M.D., MPH

Vice President, Regulatory Affairs
Purdue Pharma L.P.
todd.baumgartner@pharma.com

Patrick Beardsley, Ph.D.,

Professor, Dept of Pharmacology &
Toxicology, Institute for Drug and Alcohol
Studies, & Center for Biomarker Research and
Personalized Medicine
Virginia Commonwealth University
pbeardsl@vcu.edu

Robert Bianchi,

V. P. & Chief of Scientific and Technical Affairs
Prescription Drug Research Center
rbconsulting700@aol.com

Simon Budman, Ph.D.

President and CEO
Inflexion, Inc
simonbudman@Inflexion.com

Silvia Calderon, Ph.D.

Team Leader, Controlled Substance Staff
CDER/FDA
Silvia.calderon@fda.hhs.gov

Ling Chen, Ph.D.

Expert Mathematical Statistician
Office of Biostatistics
CDER/FDA
Ling.chen@fda.hhs.gov

Edward Cone, Ph.D.

Principal Scientist, Drug Delivery and Abuse
Deterrent Drug Products
Pinney Associates
edwardcone@verizon.net

Paul Coplan, M.S., D.Sc., MBA

Executive Director and Head,
Risk Management and Epidemiology
Purdue Pharma L.P.,
And
Adjunct Assistant Professor,
University of Pennsylvania Perelman School of
Medicine
Paul.Coplan@pharma.com

Richard Dart, M.D., Ph.D.

Director, RMPDC
Executive Director, RADARS System
Richard.Dart@rmpdc.org

Joseph Gfroerer

Statistician
Center for Behavioral Health Statistics and
Quality
SAMHSA
Joe.Gfroerer@samhsa.hhs.gov

Jack Henningfield, Ph.D.

Vice President, Research and Health Policy
Pinney Associates
and
Professor, Behavioral Biology, Adjunct
Dept. of Psychiatry and Behavioral Sciences
The Johns Hopkins University School of
Medicine
jhenning@pinneyassociates.com

Clifford J Herman

Senior Director Pharmaceutical R&D
Mallinckrodt Pharmaceuticals
Cliff.Herman@Mallinckrodt.com

Sharon Hertz, M.D.

Deputy Director, Division of Anesthesia,
Analgesia, and Addiction Products
Office of Drug Evaluation II
Office of New Drugs
CDER/FDA
Sharon.hertz@fda.hhs.gov

Nathaniel Katz, M.D., M.S.

President & CEO
Analgesic Solutions
and
Adjunct Assistant Professor of Anesthesia
Tufts University School of Medicine
NKatz@analgesicsolutions.com

Abuse Deterrent Formulation Science Meeting List of Speakers (in alphabetical order)

Michael Klein, Ph.D.

Director, Controlled Substance Staff
CDER/FDA
Michael.klein@fda.hhs.gov

Cynthia Kornegay, Ph.D.

Epidemiologist Team Lead,
Prescription Drug Abuse Team
Office of Surveillance and Epidemiology
CDER/FDA
Cynthia.kornegay@fda.hhs.gov

Penny Levin, M.S.

Director Global Regulatory Intelligence &
Policy
Teva Pharmaceuticals
Penny.Levin@tevapharm.com

Naama Levy Cooperman, Ph.D.

Director and Principal
Altreos Research Partners, Inc.
and
INC Research Consultant
nlevy-cooperman@altreos.com

Mark Mannebach, Ph.D., RPh

Vice President Regulatory Affairs
Mallinckrodt Pharmaceuticals
Mark.Mannebach@Mallinckrodt.com

Lynn McPherson, Pharm.D., BCPS, CDE

Professor & Vice Chair in the Department of
Pharmacy Practice and Science
University of Maryland School of Pharmacy
and
Director of Pharmacotherapy Services
University Care Waxter
mmcphers@rx.umaryland.edu

Srikanth C. Nallani, Ph.D.

Senior Clinical Pharmacologist
Division of Clinical Pharmacology 2
Office of Clinical Pharmacology
Office of Translational Science
CDER/FDA
Srikanth.nallani@fda.hhs.gov

Bob Rappaport, M.D.

Director, Division of Anesthesia, Analgesia,
and Addiction Products
Office of Drug Evaluation II
Office of New Drugs
CDER/FDA
Bob.rappaport@fda.hhs.gov

Andre Raw, Ph.D.

Director – Division of Chemistry I
Office of Generic Drugs
CDER/FDA
Andre.raw@fda.hhs.gov

Beatriz Rocha, MD, Ph.D.

Senior Director Global Regulatory Strategy
Covance, Inc
Beatriz.Rocha@Covance.com

Carl L. Roland, Pharm.D., M.S.

Sr. Director
Pfizer
Carl.Roland@pfizer.com

Sidney Schnoll, M.D., Ph.D.

Vice President, Pharmaceutical Risk
Management Services
Pinney Associates
sschnoll@pinneyassociates.com

Kerri Schoedel, Ph.D., BSc.

Director and Principal
Altreos Research Partners, Inc.
and
INC Research Consultant
kschoedel@altreos.com

Edward Sellers, MD, PhD, FRCPC, FACP

President and Principal
DL Global Partners, Inc.
and
Professor Emeritus, Pharmacology, Medicine
and Psychiatry
University of Toronto
e.sellers@dlglobalpartners.com

Diane Servello, B.S.

Senior Director of Regulatory Affairs
Mallinckrodt
Diane.Servello@Mallinckrodt.com

Beatrice Setnik, Ph.D.

Senior Director, Clinical Sciences
Pfizer
Beatrice.Setnik@pfizer.com

Megan Shram, Ph.D.

Director and Principal
Altreos Research Partners, Inc.
and
INC Research Consultant
mshram@altreos.com

Abuse Deterrent Formulation Science Meeting List of Speakers (in alphabetical order)

Marta Sokolowska, Ph.D.

Director, Center for Abuse Prevention and
Evaluation

Grünenthal USA, Inc.

and

Co-chair, Cross-Company Abuse Liability
Consortium

marta.sokolowska@grunenthal.com

Douglas C. Throckmorton, M.D.

Deputy Director for Regulatory Programs
CDER/FDA

Douglas.throckmorton@fda.hhs.gov

James M. Tolliver, Ph.D.

Pharmacologist, Controlled Substance Staff
CDER/FDA

James.tolliver@fda.hhs.gov

Sharon Walsh, M.S. Ph.D.

Director Center on Drug and Alcohol Research
University of Kentucky

sharon.walsh@uky.edu

Lawrence Yu, Ph.D.

Acting Director, Office of Pharmaceutical
Science

CDER/FDA

Lawrence.yu@fda.hhs.gov